Publications by authors named "Gary Ashley"

Claim this Profile
L
Long-Acting, Longer-Acting, and Ultralong-Acting Antiobesity Peptides.
Eric L Schneider, John A Hangasky, Gary W Ashley, Daniel V Santi

J Med Chem· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer.
Niranjan Meher, Anil P Bidkar, Anju Wadhwa, Kondapa Naidu Bobba, Suchi Dhrona, Gary W Ashley

Mol Cancer Ther· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The limitation of lipidation: Conversion of semaglutide from once-weekly to once-monthly dosing.
Eric L Schneider, John A Hangasky, Rocío Del Valle Fernández, Gary W Ashley, Daniel V Santi

Proc Natl Acad Sci U S A· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging long-acting IL-15 agonists for intratumoral delivery and enhanced antimetastatic activity.
John A Hangasky, Rocío Del Valle Fernández, Dimitris Stellas, Guillermo Hails, Sevasti Karaliota, Gary W Ashley

Front Immunol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer.
Niranjan Meher, Gary W Ashley, Kondapa Naidu Bobba, Anju Wadhwa, Anil P Bidkar

Adv Healthc Mater· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A platform technology for ultra-long acting intratumoral therapy.
Jeff Henise, John A Hangasky, Deborah Charych, Christopher W Carreras, Gary W Ashley

Sci Rep· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Acting Poly(ADP-ribose) Polymerase Inhibitor Prodrug for Humans.
Christopher W Carreras, Shaun D Fontaine, Ralph R Reid, Gary W Ashley, Daniel V Santi

Bioconjug Chem· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?
Daniel V Santi, Gary W Ashley, Luc Cabel, Francois-Clement Bidard

BioDrugs· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors.
Shaun D Fontaine, Christopher W Carreras, Ralph R Reid, Gary W Ashley, Daniel V Santi

Cancer Res Commun· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors.
Anish Thomas, Shaun D Fontaine, Morgan E Diolaiti, Parth Desai, Rajesh Kumar, Gary W Ashley

Mol Cancer Ther· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-Specific Membrane Antigen Targeted Deep Tumor Penetration of Polymer Nanocarriers.
Niranjan Meher, Gary W Ashley, Anil P Bidkar, Suchi Dhrona, Cyril Fong

ACS Appl Mater Interfaces· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A long-acting C-natriuretic peptide for achondroplasia.
Eric L Schneider, Christopher W Carreras, Ralph Reid, Gary W Ashley, Daniel V Santi

Proc Natl Acad Sci U S A· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attenuation of the Reaction of Michael Acceptors with Biologically Important Nucleophiles.
Brian R Hearn, Shaun D Fontaine, Eric L Schneider, Yannick Kraemer, Gary W Ashley

Bioconjug Chem· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models.
Shaun D Fontaine, Gary W Ashley, Peter J Houghton, Raushan T Kurmasheva, Morgan Diolaiti

Cancer Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PET Imaging of the EPR Effect in Tumor Xenografts Using Small 15 nm Diameter Polyethylene Glycols Labeled with Zirconium-89.
Denis R Beckford Vera, Shaun D Fontaine, Henry F VanBrocklin, Brian R Hearn, Ralph Reid, Gary W Ashley

Mol Cancer Ther· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PLX038: a PEGylated prodrug of SN-38 independent of UGT1A1 activity.
Shaun D Fontaine, Angelo D Santi, Ralph Reid, Philip C Smith, Gary W Ashley

Cancer Chemother Pharmacol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft.
Shaun D Fontaine, Byron Hann, Ralph Reid, Gary W Ashley, Daniel V Santi

Cancer Chemother Pharmacol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Controlled Release System for Long-Acting Intravitreal Delivery of Small Molecules.
Nobuo Machinaga, Gary W Ashley, Ralph Reid, Atsushi Yamasaki, Kyosuke Tanaka

Transl Vis Sci Technol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system.
Brian R Hearn, Shaun D Fontaine, Samuel J Pfaff, Eric L Schneider, Jeff Henise, Gary W Ashley

J Control Release· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical sealants with tunable swelling, burst pressures, and biodegradation rates.
Jeff Henise, Brian R Hearn, Daniel V Santi, Hiroyuki Kamata, Takamasa Sakai, Gary W Ashley

J Biomed Mater Res B Appl Biomater· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist.
Eric L Schneider, Brian R Hearn, Samuel J Pfaff, Ralph Reid, David G Parkes, Gary W Ashley

ACS Chem Biol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Approach for Half-Life Extension of Small Antibody Fragments That Does Not Affect Tissue Uptake.
Eric L Schneider, Brian R Hearn, Samuel J Pfaff, Shaun D Fontaine, Ralph Reid, Gary W Ashley

Bioconjug Chem· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneously Administered Self-Cleaving Hydrogel-Octreotide Conjugates Provide Very Long-Acting Octreotide.
Eric L Schneider, Jeff Henise, Ralph Reid, Gary W Ashley, Daniel V Santi

Bioconjug Chem· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hydrogel Drug Delivery System Using Self-Cleaving Covalent Linkers for Once-a-Week Administration of Exenatide.
Eric L Schneider, Jeff Henise, Ralph Reid, Gary W Ashley, Daniel V Santi

Bioconjug Chem· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Half-life extension of the HIV-fusion inhibitor peptide TRI-1144 using a novel linker technology.
Eric L Schneider, Gary W Ashley, Lieve Dillen, Bart Stoops, Nigel E Austin

Eur J Pharm Biopharm· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis